期刊文献+

大剂量碘油治疗原发性巨块型肝癌的疗效分析 被引量:4

The utility of large dosage lipiodol treatment in huge primary hepatic carcinoma
下载PDF
导出
摘要 【目的】回顾性分析巨块型肝癌经肝动脉灌注化疗并大剂量碘油加化疗药栓塞治疗的临床疗效。【方法】150例原发性巨块型肝癌患者,经皮股动脉穿刺插管至肝动脉,化疗栓塞治疗肝癌;碘油用量为20~60 ml。再注入明胶海绵颗粒栓塞治疗。发现肝外肿瘤供血动脉,超选择插管化疗栓塞后,注入适量明胶海绵栓塞治疗。【结果】治疗的总有效率(RR)为77.3%,治疗后1、2、3年生存率分别为78%、59.3%、45.3%。介入术后未出现严重并发症。【结论】原发性巨块型肝癌大剂量碘油栓塞联合肝外肿瘤供血动脉介入治疗,对于提高疗效具有重要意义。 【Objective】To investigate the clinical efficacy of transcatheter arterial chemoembolization(TACE)with large dosage iodized oil(lipiodol)in huge primary hepatic carcinoma(PHC)via injecting from hepatic artery.【Methods】One hundred fifty cases of diagnosed huge primary liver cancerwere treated by TACE through trans-femoral-artery-catheterwith 20~60ml lipiodol and sufficientgelatin sponge.Super-selective catheterization and transcatheter dual arterial chemoembolization to extraheptic arterialwas preformed.【Results】The overall response rate was 77.3%,the 1,2,3 years survival rates after treatment were 78%、 45.3%、11.3%.No severe complications happened in this series.【Conclusion】High dose lipiodol TACE combinedwith interventional treatment-ofextrahepatic arterieshave very important clinical significance forbetter efficacy of huge primary liver cancer patients.
出处 《武警医学院学报》 CAS 2011年第6期449-451,共3页 Acta Academiae Medicinae CPAPF
关键词 原发性巨块型肝癌 经动脉栓塞化疗 碘油 疗效 Huge primary liver cancer Transcatheter arterial chemoembolization Lipiodol Clinical efficacy
  • 相关文献

参考文献7

  • 1杨秉辉,丛文铭,周晓军,陈孝平,杨甲梅,樊嘉,王建华,杨仁杰,李槐,蒋国梁,曾昭冲,陈敏华,陈敏山,梁萍,吕明德,罗荣城,刘鲁明,秦叔逵,叶胜龙,吴孟超,汤钊猷,孙燕,管忠震.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3):259-269. 被引量:313
  • 2[3]周际昌.实用肿瘤内科学[M].第2版.北京:人民卫生出版社,2006:266.
  • 3Ebied OM,FederleMP,Cart BI,et a.l Evaluation of responses to chemoembolization in patientswith unresectable hepatocellular carcinoma.Cancer,2003,97 (4):1042-1050.
  • 4王小林,龚高全,王建华,颜志平,程洁敏,钱晟,陈颐.原发性巨块型肝癌经动脉大剂量碘化油栓塞的应用分析[J].复旦学报(医学版),2009,36(1):79-82. 被引量:13
  • 5Kim HC,Chung JW,LeeW,et al.Recognizing extrahepatic collateral vessels that supply hepatecellular carcinoma to avoid complications of transcatheter arterial chemoembolization.Radiographics,2005,25 Suppl 1:S25-39.
  • 6Chung JW,KimHC,Yoon JH,et al.Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma:Prevalence and Causative Factors of Extrahepatic CollateralArteries in 479 Patients[J].Korean J Radio,2006,7(4):257-266.
  • 7邹俊民,湛进城,张振明.大剂量碘油与常规TACE治疗巨块肝癌的对比研究[J].影像诊断与介入放射学,2005,14(2):93-95. 被引量:3

二级参考文献9

  • 1罗鹏飞,陈晓明.肝癌介入治疗中的完全性充填法[J].中华放射学杂志,1996,30(2):79-79. 被引量:53
  • 2Pelletier G,Ducreux M,Gag F,et al. Hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized [J]. J Hepatol,1998,2:129- 132.
  • 3Dumortier J, Chapuis F, Borson O, et al. Unreseetable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients[J]. Dig Liver Dis, 2006,38(2) :125-133.
  • 4Hwang J I, Chow WK, Hung SW,et al. Development of a safety index of transarterial chemoembolization for hepatocellular carcinoma to prevent acute liver damage[J]. Anticancer Res, 2005,25(3c) :2 551 - 2 554.
  • 5Suh SH,Won JY, Lee do Y, et al. Chemoembolization of the left inferior phrenic artery in patients with hepatoceltular carcinoma: radiographic findings and clinical outcome[J]. J Vasc Interv Radiol,2005,16(12) :1 741 - 1 745.
  • 6Miyayama S, Matsui O, Taki supply to hepatocellular K, et al. Extrahepatic blood carcinoma : angiographic demonstration and transcatheter arterial ehemoembolization [J]. Cardiovasc Intervent Radiol, 2006,29(1 ) : 39- 48.
  • 7程红岩,陈栋,徐爱民,贾雨辰.大剂量碘油治疗大肝癌的初步体会[J].介入放射学杂志,2002,11(1):24-26. 被引量:15
  • 8刘嵘,王建华,周康荣,颜志平,程洁敏,钱晟,刘清欣,龚高全.肝动脉化疗栓塞治疗原发性肝癌中碘油沉积良好患者疗效观察[J].介入放射学杂志,2001,10(4):212-214. 被引量:42
  • 9龚高全,王小林,周康荣,王建华,颜志平,程洁敏,钱晟,刘清欣,陈颐.肝癌伴门静脉癌栓的金属内支架治疗的初步研究[J].临床放射学杂志,2003,22(6):498-500. 被引量:31

共引文献329

同被引文献49

  • 1程红岩,陈栋,徐爱民.阻断动脉血流治疗少血供恶性肝肿瘤的初步研究[J].中国介入影像与治疗学,2004,1(1):60-64. 被引量:9
  • 2邹俊民,湛进城,张振明.大剂量碘油与常规TACE治疗巨块肝癌的对比研究[J].影像诊断与介入放射学,2005,14(2):93-95. 被引量:3
  • 3陈光斌,李江山,邹文远,李晓霞,汪汉.利多卡因-碘化油乳剂在肝癌化疗栓塞术中的应用价值[J].实用放射学杂志,2006,22(6):760-761. 被引量:1
  • 4肖金成,张宏凯,张建伟.连续小剂量TACE治疗肝细胞黄疸性肝癌[J].医药论坛杂志,2006,27(11):107-107. 被引量:6
  • 5Tomuleasa C, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma[J]. J Gastrotestin Liver Dis, 2010, 19(1): 61-67.
  • 6Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma[J]. J Hepatol, 2010, 52(2): 280-281.
  • 7Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma [J]. J Hepatol, 2010, 52 (6); 872-879.
  • 8Pallini R, Ricci-Vitiani L, Montano N, et al. Expression of the stem cell marker CD 133 in recurrent glioblastoma and its value for prognosis[J]. Cancer, 2011, 117(1): 162-174.
  • 9Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells[J]. J Clin Invest, 2010, 120(9): 3326-3339.
  • 10Christ B, Stock P, Doliinger MM. CD 13: Waving the fleg for a novel cancer stem cell target[J]. Hepatology, 2011, 53(4): 1388-1390.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部